Researchers conducting the Com-Cov clinical study investigating alternating doses of the AstraZeneca and the Pfizer-BioNTech COVID-19 vaccines announced that the program now includes the Moderna and Novavax vaccines.
Study volunteers will receive either the AstraZeneca or Pfizer vaccine, will be randomly allocated to receive either the same vaccine for their second dose or a dose of the COVID-19 vaccines produced by Moderna or Novavax.
The six new ‘arms’ of the Com-Cov trial will each recruit 175 candidates, adding a further 1,050 recruits into this innovative program.
Mixing COVID-19 Vaccine Study Adds Two Other Vaccines
Response to One COVID-19 Vaccine Dose Strong in Previously Infected
Neutralizing antibody titer is higher after one dose of mRNA vaccine than after two vaccine doses in previously uninfected persons
Booster Shots a Likely Reality for COVID-19-Vaccinated Americans
And, CDC has scheduled a new emergency hearing on the safety of J&J vaccine for April 23
Hemorrhagic Stroke + COVID-19 Doubles Risk for In-Hospital Mortality
In addition to increased risk for death, hospital and ICU lengths of stay are longer
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of April 12 to 16, 2021. This …
Number of Preventive Med Doctors Unlikely to Match U.S. Needs
Number of self-identified preventive medicine physicians has decreased since 2000, with leveling off in past four years
Senators Urge Biden to Waive Rules That Restrict COVID-19 Vaccine Production
Waiver could open the door for generic or other manufacturers to make more vaccines
Europe Surpasses 1 Million COVID-19 Deaths
WHO wants to emphasize the need for Europe to maintain social distancing and speed up vaccinations